$12.24
0.16% yesterday
Nasdaq, Sep 27, 10:10 pm CET
ISIN
US86150R1077
Symbol
STOK

Stoke Therapeutics Inc Target price 2024 - Analyst rating & recommendation

Stoke Therapeutics Inc Classifications & Recommendation:

Buy
89%
Hold
11%

Stoke Therapeutics Inc Price Target

Target Price $22.14
Price $12.24
Potential
Number of Estimates 7
7 Analysts have issued a price target Stoke Therapeutics Inc 2025 . The average Stoke Therapeutics Inc target price is $22.14. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 8 Analysts recommend Stoke Therapeutics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Stoke Therapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the Stoke Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 8.78 14.87
29.25% 69.35%
EBITDA Margin -1,253.30% -795.29%
54.27% 36.54%
Net Margin -1,417.97% -765.62%
29.38% 46.01%

9 Analysts have issued a sales forecast Stoke Therapeutics Inc 2024 . The average Stoke Therapeutics Inc sales estimate is

$14.9m
Unlock
. This is
1.92% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$19.0m 25.64%
Unlock
, the lowest is
$9.0m 40.63%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $8.8m 29.25%
2024
$14.9m 69.35%
Unlock
2025
$15.8m 6.57%
Unlock
2026
$28.2m 77.72%
Unlock
2027
$77.6m 175.54%
Unlock
2028
$144m 86.04%
Unlock

3 Analysts have issued an Stoke Therapeutics Inc EBITDA forecast 2024. The average Stoke Therapeutics Inc EBITDA estimate is

$-118m
Unlock
. This is
7.60% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-94.4m 14.14%
Unlock
, the lowest is
$-138m 25.57%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-110m 9.15%
2024
$-118m 7.46%
Unlock
2025
$-142m 19.74%
Unlock
2026
$-152m 7.07%
Unlock
2027
$-46.8m 69.15%
Unlock
2028
$21.3m 145.54%
Unlock

EBITDA Margin

2023 -1,253.30% 54.27%
2024
-795.29% 36.54%
Unlock
2025
-893.57% 12.36%
Unlock
2026
-538.35% 39.75%
Unlock
2027
-60.27% 88.80%
Unlock
2028
14.75% 124.47%
Unlock

5 Stoke Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Stoke Therapeutics Inc net profit estimate is

$-114m
Unlock
. This is
0.63% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-106m 7.31%
Unlock
, the lowest is
$-135m 17.88%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-124m 8.46%
2024
$-114m 8.56%
Unlock
2025
$-124m 9.35%
Unlock
2026
$-128m 2.84%
Unlock
2027
$-52.1m 59.34%
Unlock
2028
$-2.4m 95.49%
Unlock

Net Margin

2023 -1,417.97% 29.38%
2024
-765.62% 46.01%
Unlock
2025
-785.58% 2.61%
Unlock
2026
-454.59% 42.13%
Unlock
2027
-67.08% 85.24%
Unlock
2028
-1.63% 97.57%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -2.38 -2.18
8.46% 8.40%
P/E negative
EV/Sales 24.76

5 Analysts have issued a Stoke Therapeutics Inc forecast for earnings per share. The average Stoke Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-2.18
Unlock
. This is
0.46% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-2.03 7.31%
Unlock
, the lowest is
$-2.58 17.81%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-2.38 8.46%
2024
$-2.18 8.40%
Unlock
2025
$-2.38 9.17%
Unlock
2026
$-2.45 2.94%
Unlock
2027
$-1.00 59.18%
Unlock
2028
$-0.05 95.00%
Unlock

P/E ratio

Current -5.60 239.39%
2024
-5.62 0.36%
Unlock
2025
-5.14 8.54%
Unlock
2026
-5.00 2.72%
Unlock
2027
-12.30 146.00%
Unlock
2028
-272.00 2,111.38%
Unlock

Based on analysts' sales estimates for 2024, the Stoke Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

24.76
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
43.34
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 24.29 604.99%
2024
24.76 1.94%
Unlock
2025
23.24 6.16%
Unlock
2026
13.07 43.73%
Unlock
2027
4.75 63.71%
Unlock
2028
2.55 46.25%
Unlock

P/S ratio

Current 42.51 103.35%
2024
43.34 1.96%
Unlock
2025
40.67 6.16%
Unlock
2026
22.88 43.73%
Unlock
2027
8.30 63.71%
Unlock
2028
4.46 46.25%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today